[216 Pages] From 2022 to 2028, the global seasonal affective disorder therapeutics market is slated to rise at a CAGR of 4.3%. Currently, the market accounts for a valuation of US$ 848.2 Mn, and is projected to close in on US$ 1.1 Bn by the end of 2028.
| Attribute | Details |
|---|---|
| Seasonal Affective Disorder Therapeutics Market Size (2022) | US$ 848.2 Million |
| Projected Market Value (2028) | US$ 1.1 Billion |
| Global Market Growth Rate (2022 to 2028) | 4.3% CAGR |
| North America Market Share | 38.4% |
Sales of seasonal affective disorder therapeutic drugs and devices account for a share of 4.6% in the global depressive disorder treatment market. Preference and popularity of bright light therapy among physicians and patients is expected to be a major trend driving seasonal affective disorder therapeutics demand growth through 2028.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 4.29% |
| H1, 2022 Projected | 4.34% |
| H1, 2022 Outlook | 4.24% |
| BPS Change - H1, 2022 (O) – H1, 2022 (P) | (-) 10 ↓ |
| BPS Change – H1, 2022 (O) – H1, 2021 | (-) 05 ↓ |
The market for seasonal affective disorder therapeutics is subject to change as per the regulatory dynamics for drugs, in accordance to macroeconomic and industrial standards.
The variation between the BPS values observed within this market in H1, 2022 - outlook over H1, 2022 projected reflects a decline of 10 BPS units. Additionally, a drop in BPS growth in H1-2022 over H1-2021 by 05 Basis Point Share (BPS) is demonstrated by the market.
The decline in the BPS values is associated with the limited evidence for the effectiveness of light therapy when compared with other available preventive options. Moreover, patient preference towards treatment modalities is dominant for the preventive treatment of seasonal affective disorder.
On the contrary, the market is expected to gain traction in terms of growth and sales outlook during the forecast period. This is supported with the development of second-generation antidepressants for the treatment of seasonal affective disorder in adults.
The key developments in the market include the FDA approval of an extended-release antidepressant, bupropion, for the prevention of recurrent seasonal affective disorder with major depressive episodes.
Anxiety and depression among the general population have seen a substantial spike over the past few years and this has majorly influenced the healthcare industry in multiple ways. The seasonal affective disorder therapeutics market exhibited expansion at a CAGR of 3.7% from 2013 to 2021.
Increasing prevalence of seasonal affective disorders, rising instances of depression among the general population, increasing availability of treatment options, and rising research and development activities in therapeutics are some major factors that are anticipated to influence seasonal affective disorder therapeutics demand over the forecast period.
Research & development activities are of paramount importance in helping create effective therapeutic solutions for seasonal affective disorders. Seasonal affective disorder therapeutic providers are focusing on expanding their research scope and creating novel therapeutic solutions for patients.
Demand for seasonal affective disorder therapeutics is estimated to rise at a CAGR of 4.3% from 2022 to 2028.
“Increasing Popularity of Light Therapy to Positively Impact Market Potential”
Bright light therapy has emerged as one of the most popular aspects of the seasonal affective disorder therapeutics marketplace in recent years. This therapy provides a rapid anti-depressant effect on patients and has seen an increase in recommendation by physicians and health professionals.
Principal Consultant
“Lack of Research Data & Adverse Effects of Anti-depressants to Majorly Hamper Market Growth”
Scarce research data and low availability of information on seasonal affective disorders are anticipated to be major barriers for seasonal affective disorder therapeutics providers. Inadequate research data on effects of bright light and blue light on the treatment of patients is expected to restrain market potential.
Adverse effects associated with excessive use of anti-depressants and other therapy drugs are predicted to be a major issue in the seasonal affective disorder therapeutics industry landscape over the forecast period.
Statistical analysis of seasonal affective disorder therapeutics market metrics for regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA) has been assessed in this market study.
Accounting for a dominative market share of 38.4% in the global seasonal affective disorder therapeutics marketplace, North America is anticipated to provide a highly beneficial setting for seasonal affective disorder therapeutic companies. Increasing prevalence of seasonal affective disorders and rising focus on healthcare are expected to be major trends in this region.
Second to North America, the Europe seasonal affective disorder therapeutics product market accounts for a market share of 29.5% in 2022. Increasing healthcare expenditure and rising research and development activities for seasonal affective disorders are expected to be prominent trends in this region through 2028.
Rising awareness about anxiety and depression is expected to majorly boost awareness about seasonal affective disorders in regions of East Asia and South Asia. Currently, East Asia and South Asia account for market shares of 18.5% and 7.5% in the global seasonal affective disorder therapeutics market.
Lack of awareness, low research activity, and underdeveloped healthcare infrastructure are expected to lead to slow growth in seasonal affective disorder therapeutics demand in regions of Oceania and the MEA. At present, the MEA and Oceania regions hold market shares of 1.5% and 1%, respectively, in the global seasonal affective disorder therapeutics industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“Rising Awareness & Focus on Mental Health Expected to Positively Impact Market Expansion”
Mental health has emerged as one of the most concerning healthcare issues in India over the past few years and this has also bolstered demand for multiple seasonal affective disorder treatments. Developing healthcare infrastructure, lack of awareness, and lack of availability of treatments are expected to be prominent trends controlling demand for seasonal affective disorder therapeutics in India.
“High Prevalence of Multiple Seasonal Affective Disorders to Positively Influence Demand”
The U.S. has seen a substantial increase in instances of anxiety and depression-related disorders and this has fostered a demand for seasonal affective disorder therapeutics. Rising instances of bipolar disorders is the major trend that drives the market potential for this nation.
High research & development activities and increasing availability of treatment options are also expected to favor seasonal affective disorder therapeutics demand.
Seasonal affective disorder therapeutic providers are focusing on developing and launching novel treatment solutions to maximize their revenue potential in the nation.
“High Incidence of Bipolar Disorders to Majorly Govern Seasonal Affective Disorder Therapeutics Demand”
Bipolar disorder has emerged as one of the most prominent seasonal affective disorders over recent years and this has led to its substantial influence on the seasonal affective disorder therapeutics marketplace.
This disorder is expected to hold a dominant market share over the forecast period and is expected to be a majorly influential segment through 2028.
The unexpected and sudden emergence of the COVID-19 pandemic adversely affected the mental health of people all over the globe and led to an increase in anxiety and depression in individuals.
While the seasonal affective disorder therapeutics market saw a negative growth trend in 2020 due to disruptions to supply chains and lockdown mandates, the seasonal affective disorder therapeutics market is expected to see high demand in the post-pandemic era.
Seasonal affective disorder therapeutic providers are investing in the research & development of novel therapeutics specific to seasonal affective disorders. Seasonal affective disorder therapeutic equipment manufacturing companies are also adopting organic and inorganic strategies to increase awareness about seasonal affective disorders and boost their sales revenue.
As it is the first FDA-approved drug of its kind, it is expected to see high demand over the coming years.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | US$ Mn for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Turkey, South Africa, and GCC Countries |
| Key Market Segments Covered | Treatment Type, Disorder Type, Distribution Channel, Region |
| Key Companies Profiled | Allergan plc.; Eli Lily Company; GlaxoSmithKline; Pfizer Inc.; Teva Pharmaceuticals; Bausch Health Companies Inc.; F. Hoffman-La Roche AG; Mylan N.V.; Sanofi AG; Novartis AG; Janssen Pharmaceuticals Inc.; Koninklije Philips N.V.; The Sunbox Company; Beurer GmbH; Lucimed S.A. |
| Pricing | Available upon Request |
The global seasonal affective disorder therapeutics market is anticipated to attain a valuation of US$ 1.1 Bn by the end of 2028.
Key suppliers of seasonal affective disorder therapeutic systems are F. Hoffman-La Roche AG, Mylan N.V., Sanofi AG, Novartis AG, Janssen Pharmaceuticals Inc., Koninklije Philips N.V., and The Sunbox Company.
Currently, the North America seasonal affective disorder therapeutics market holds a prominent share of 38.4% in the global industry.
From 2022 to 2028, the seasonal affective disorder therapeutics market is predicted to expand at a CAGR of 4.3%.
In 2022, the seasonal affective disorder therapeutics market accounts for a value of US$ 848.2 Mn.
1. Executive Summary
1.1. Global Market Outlook
1.2. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Macro-Economic Factors
3.2. Forecast Factors - Relevance & Impact
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Restraints
3.3.3. Opportunities
3.3.4. Trends
4. Key Success Factors
4.1. Key Regulations
4.2. Disease Epidemiology
5. Global Seasonal Affective Disorder Therapeutics Market Volume Analysis 2013-2021 and Forecast, 2022-2028
5.1. Historical Market Volume (‘000 Units) Analysis, 2013-2021
5.2. Current and Future Market Volume (‘000 Units) Projections, 2022-2028
6. Global Seasonal Affective Disorder Therapeutics Market - Pricing Analysis
6.1. Regional Pricing Analysis By Device Type
6.2. Global Average Pricing Analysis Benchmark
7. Global Seasonal Affective Disorder Therapeutics Market Value Analysis 2013-2021 and Forecast, 2022-2028
7.1. Historical Market Value (US$ Mn) Analysis, 2013-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2028
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028, by Treatment Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2013 - 2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment Type, 2022 – 2022
8.3.1. Drugs
8.3.1.1. Selective serotonin reuptake inhibitors (SSRIs)
8.3.1.2. Norepinephrine-dopamine reuptake inhibitor (NDRI)
8.3.1.3. Serotonin and norepinephrine reuptake inhibitors (SNRIs)
8.3.1.4. Monoamine oxidase inhibitors (MAOIs)
8.3.1.5. Tricyclic antidepressants (TCAs)
8.3.2. Devices
8.3.2.1. Light Boxes
8.3.2.2. Dawn Stimulators
8.3.2.3. Desk Lamps
8.3.2.4. Sun Visors
8.4. Market Attractiveness Analysis By Treatment Type
9. Global Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028, by Disorder Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Disorder Type, 2013 - 2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disorder Type, 2022 - 2022
9.3.1. Unipolar Disorder
9.3.1.1. Fall-winter onset
9.3.1.2. Spring-summer onset
9.3.1.2. Bipolar Disorder
9.4. Market Attractiveness Analysis By Sales Channel
10. Global Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028, by Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013 - 2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022 - 2022
10.3.1. Institutional Sales
10.3.1.1. Hospitals
10.3.1.2. Clinics
10.3.1.3. Wellness Centers & Spas
10.3.2. Retail Sales
10.3.2.1. Retail Pharmacies
10.3.2.2. Drug Stores
10.3.2.3. Online Sales
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2013 - 2021
11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 - 2022
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Middle East and Africa (MEA)
11.3.5. East Asia
11.3.6. South Asia
11.3.7. Oceania
11.4. Market Attractiveness Analysis By Region
12. North America Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2013 - 2021
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2028
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Treatment Type
12.3.3. By Disorder Type
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
13. Latin America Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2013 - 2021
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2028
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Treatment Type
13.3.3. By Disorder Type
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
14. Europe Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2013 - 2021
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2028
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. Russia
14.3.1.7. Rest of Europe
14.3.2. By Treatment Type
14.3.3. By Disorder Type
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
15. South Asia Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2013 - 2021
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2028
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Indonesia
15.3.1.4. Malaysia
15.3.1.5. Rest of South Asia
15.3.2. By Treatment Type
15.3.3. By Disorder Type
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
16. East Asia Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2013 - 2021
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2028
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Treatment Type
16.3.3. By Disorder Type
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
17. Oceania Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2013 - 2021
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2028
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Treatment Type
17.3.3. By Disorder Type
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
18. Middle East and Africa Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2013 - 2021
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2028
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. South Africa
18.3.1.3. Rest of Middle East and Africa
18.3.2. By Treatment Type
18.3.3. By Disorder Type
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
19. Emerging Countries Seasonal Affective Disorder Therapeutics Market Analysis 2013-2021 and Forecast 2022-2028
19.1. Introduction
19.1.1. Market Value Proportion Analysis, By Key Countries
19.1.2. Global Vs. Country Growth Comparison
19.2. China Seasonal Affective Disorder Therapeutics Market Analysis
19.2.1. Introduction
19.2.2. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
19.2.2.1. By Treatment Type
19.2.2.2. By Disorder Type
19.2.2.3. By Distribution Channel
19.3. Russia Seasonal Affective Disorder Therapeutics Market Analysis
19.3.1. Introduction
19.3.2. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
19.3.2.1. By Treatment Type
19.3.2.2. By Disorder Type
19.3.2.3. By Distribution Channel
19.4. Indonesia Seasonal Affective Disorder Therapeutics Market Analysis
19.4.1. Introduction
19.4.2. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
19.4.2.1. By Treatment Type
19.4.2.2. By Disorder Type
19.4.2.3. By Distribution Channel
19.4.3. Russia Seasonal Affective Disorder Therapeutics Market - Competition Landscape
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Deep Dive
20.2.1. Allergan plc
20.2.1.1. Overview
20.2.1.2. Product Portfolio
20.2.1.3. Analyst Commentary
20.2.1.4. Key Financials
20.2.1.5. Strategy Overview
20.2.2. Eli Lily Company
20.2.3. GlaxoSmithKline
20.2.4. Pfizer Inc.
20.2.5. Teva Pharmaceuticals
20.2.6. Bausch Health Companies Inc.
20.2.7. F. Hoffmann-La Roche AG
20.2.8. Mylan N.V.
20.2.8.1. Sanofi AG
20.2.9. Novartis AG
20.2.10. Janssen Pharmaceuticals, Inc.
20.2.11. Koninklijke Philips N.V
20.2.12. The Sunbox Company
20.2.13. Beurer GmbH
20.2.14. Lucimed S.A.
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Seasonal Affective Disorder Therapeutics Market
